

Patient - PACT

New Clinical Trial and Research



Trial title	GALACTIC-1 - A randomised, double-blind, multicentre, parallel, placebo-controlled Phase 2b study in participants with idiopathic pulmonary fibrosis (IPF) investigating the efficacy and safety of GB0139, an inhaled galectin-3 inhibitor administered via a dry powder inhaler (DPI) over 52 weeks
Trial synopsis	The main purpose of this study is to assess the efficacy of GB0139, compared to the placebo, on lung function and IPF disease in general. GB0139 (formerly TD139) is a small molecule inhibitor of galectin-3, a protein involved in scarring (fibrosis) of the lungs and other organs. Levels of galectin-3 are particularly high in the lungs of IPF patients. GB0139 is a dry powder inhaler that is taken once per day. This study will also continue to measure the safety of GB0139 and how well it is tolerated (for example if you get any side effects while on the study drug).
Investigational medicinal product, comparator and randomisation	GB0139 Active dose A / inhalation; Matching placebo / inhalation; 2:1
Disease target	Idiopathic Pulmonary Fibrosis (IPF)
Sponsor	Galecto
Duration	6 weeks for screening followed by 52 weeks of treatment and 2 weeks follow up.
Trial Status	Recruiting
Lead site(s) in Australia	TrialsWest, Spearwood, WA Flinders Medical Centre, Bedford Park, SA
Lead site(s) in New Zealand	Not applicable
Additional sites	Respiratory Clinical Trials, SA
Contact	pactcoordinator@cre-pf.org.au